

## Supplementary Online Content

Lam BL, Feuer WJ, Schiffman JC, et al. Trial end points and natural history in patients with G11778A Leber hereditary optic neuropathy: preparation for gene therapy clinical trial. *JAMA Ophthalmol*. Published online February 13, 2014. doi:10.1001/jamaophthalmol.2013.7971.

**eTable 1.** Follow-up visits of affected LHON patients

**eTable 2.** Improvement of visual acuity by 15 ETDRS letters from baseline (both eyes averaged) for patients taking idebenone compared to those not taking idebenone

**eFigure 1.** Relationship between RNFL thickness and ETDRS acuity for four individual patients with improving acuity

**eFigure 2.** Visual acuity and HVF MD of participants with onset of visual symptoms within two years of study enrollment





This supplementary material has been provided by the authors to give readers additional information about their work.

eTable 1. Follow-Up Visits of Affected LHON Patients		
Follow Up Visit (month)	Number (%) of patients completing each visit	
	All visits	Last Visit
6	43 (98%)	4 (9%)
12	40 (91%)	5 (11%)
18	33 (75%)	4 (9%)
24	31 (70%)	5 (11%)
30	25 (57%)	8 (18%)
36	18 (41%)	18 (41%)

eTable 2. Improvement of visual acuity by 15 ETDRS letters from baseline (both eyes averaged) for patients taking Idebenone compared to those not taking Idebenone. There was no significant difference between the groups ( $p=0.41$ , Fisher exact test).

Patient taking Idebenone	N (%) with acuity improved	Total
Yes	4 (27%)	15
No	4 (14%)	29

eFigure 1. Relationship between RNFL thickness and ETDRS acuity for four individual patients with improving acuity. A, bilateral improvement; B, initially swollen nerve; C, unilateral involvement; and D, delayed improvement in one eye.



eFigure 2. Visual acuity and HVF MD of participants with onset of visual symptoms within two years of study enrollment. A) and B) visual acuity of participants with no and with idebenone exposure, respectively. C) and D) HVF MD of participants with no and with idebenone exposure, respectively. The values of the 2 eyes are averaged. (The patient that received stem cells and the other who received epi-743 are charted.)

